Reduction of Lipoprotein(a) by Immunospecific LDL Apheresis

2015 ◽  
pp. 219-222 ◽  
Author(s):  
Christoph Gruber ◽  
Klaus Swoboda ◽  
Johann Pidlich ◽  
Michael Gottsauner-Wolf ◽  
Gere Sunder-Plassmann ◽  
...  
Keyword(s):  
Ldl Apheresis ◽  
Lipoprotein A

Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia

1993 ◽  
Vol 100 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Junji Koizumi ◽  
Ichiro Koizumi ◽  
Yoshihide Uno ◽  
Akihiro Inazu ◽  
Kouvi Kajinami ◽  
...  
Keyword(s):  
Familial Hypercholesterolemia ◽  
Dextran Sulfate ◽  
Ldl Apheresis ◽  
Lipoprotein A ◽  
Cellulose Column

scholarly journals LDL-Apheresis: Technical and Clinical Aspects

2012 ◽  
Vol 2012 ◽  
pp. 1-19 ◽  
Author(s):  
Rolf Bambauer ◽  
Carolin Bambauer ◽  
Boris Lehmann ◽  
Reinhard Latza ◽  
Ralf Schiel
Keyword(s):  
Therapeutic Option ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Clinical Aspects ◽  
Published Data ◽  
Ldl Apheresis ◽  
Lipoprotein A ◽  
Regular Treatment ◽  
Lipid Lowering Drugs

The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density lipoprotein (LDL) apheresis is the therapeutic option. Today, there are five different LDL-apheresis systems available: cascade filtration or lipid filtration, immunoadsorption, heparin-induced LDL precipitation, dextran sulfate LDL adsorption, and the LDL hemoperfusion. There is a strong correlation between hyperlipidemia and atherosclerosis. Besides the elimination of other risk factors, in severe hyperlipidemia therapeutic strategies should focus on a drastic reduction of serum lipoproteins. Despite maximum conventional therapy with a combination of different kinds of lipid-lowering drugs, sometimes the goal of therapy cannot be reached. Hence, in such patients, treatment with LDL-apheresis is indicated. Technical and clinical aspects of these five different LDL-apheresis methods are shown here. There were no significant differences with respect to or concerning all cholesterols, or triglycerides observed. With respect to elevated lipoprotein (a) levels, however, the immunoadsorption method seems to be most effective. The different published data clearly demonstrate that treatment with LDL-apheresis in patients suffering from severe hyperlipidemia refractory to maximum conservative therapy is effective and safe in long-term application.

Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels

1990 ◽  
Vol 195 (1-2) ◽  
pp. 9-15 ◽  
Author(s):  
Michael Matthias Ritter ◽  
Klaus Sühler ◽  
Werner Richter ◽  
Peter Schwandt
Keyword(s):  
Serum Levels ◽  
Long Term Effects ◽  
Ldl Apheresis ◽  
Lipoprotein A ◽  
Short And Long Term

Effects of immunospecific LDL apheresis on lipoprotein (a) serum levels

1995 ◽  
Vol 115 ◽  
pp. S93
Author(s):  
M. Jansen ◽  
K. Derfler ◽  
H. Hysek ◽  
J. Pidlich ◽  
W. Druml
Keyword(s):  
Serum Levels ◽  
Ldl Apheresis ◽  
Lipoprotein A

Effect of Nicotinic acid/Laropiprant on lipoprotein (a) in patients receiving LDL apheresis

2011 ◽  
Vol 218 (2) ◽  
pp. e11-e12
Author(s):  
Suzanne Watkins ◽  
Anne Govier ◽  
Hazel Weedon ◽  
Dev Datta
Keyword(s):  
Nicotinic Acid ◽  
Ldl Apheresis ◽  
Lipoprotein A

LDL-Apheresis in Two Patients with Extremely Elevated Lipoprotein (a) Levels

1995 ◽  
Vol 18 (5) ◽  
pp. 286-290 ◽  
Author(s):  
R. Bambauer ◽  
R. Schiel ◽  
H.E. Keller ◽  
R. Latza
Keyword(s):  
Ldl Cholesterol ◽  
Myocardial Infarctions ◽  
Lipid Lowering ◽  
Fibrinogen Concentration ◽  
Ldl Apheresis ◽  
Premature Atherosclerosis ◽  
Lipoprotein A ◽  
Diet Regimen ◽  
Caucasian Patients ◽  
Percutaneous Transluminal

Hyperlipidemia and elevated lipoprotein (a) [Lp(a)] levels have been linked to the development and progression of premature atherosclerosis. Two male Caucasian patients (36 and 42 years old) with heterozygous familial hypercholesterolemia and extremely elevated Lp(a) concentrations, resistant to diet regimen and lipid lowering drugs, were treated with LDL-apheresis for 55 months (liposorber system, KanekaR, Japan) and 15 months (immunoadsorption system, special Lp(a) columns, LipopakR, Pocard, Russia). Lp(a) dropped on average by 50%, total cholesterol by 27%, LDL-cholesterol by 42%, triglycerides by 43% and the fibrinogen concentration by 16%. Prior to treatment, both patients had suffered three myocardial infarctions. Four and six coronary angiographies with two and four percutaneous transluminal angioplasties (PTCA) were necessary. Since the treatment with LDL-apheresis neither myocardial infarctions nor cardiac complaints have been observed, and both patients have reported better performance. Available data suggest that LDL-apheresis may be effective in the treatment of patients with extremely high Lp(a) concentration.

Isolation of Lipoprotein (a) Using the Regenerate of a Dextran Sulfate Cellulose LDL Apheresis System

1994 ◽  
Vol 5 (2) ◽  
pp. 112-117 ◽  
Author(s):  
E. Gross ◽  
W. Marz ◽  
R. Siekmeier ◽  
I. Scharrer ◽  
W. Gross
Keyword(s):  
Dextran Sulfate ◽  
Ldl Apheresis ◽  
Lipoprotein A
Sign in / Sign up

Export Citation Format

Share Document